Mineralys Therapeutics

About Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to treat hypertension and related comorbidities including chronic kidney disease, obstructive sleep apnea, and other diseases driven by dysregulated aldosterone. The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is advancing this therapeutic approach through clinical development to address unmet medical needs in cardiovascular and renal disease management.